Skip to main content
SpringerLink
Log in

Biological agents used to treat rheumatoid arthritis (RA) are used by less than 3% of patients as first-line therapy and less than 4% as second-line therapy, despite being approved for first-line use,

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources.Although Approved for First-Line Use, Biologic Agents for the Treatment of Rheumatoid Arthritis are Used by Less than 3% of Patients on First-Line and Less than 4% on Second-Line. Media Release: 28 Nov 2006. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biological agents used to treat rheumatoid arthritis (RA) are used by less than 3% of patients as first-line therapy and less than 4% as second-line therapy, despite being approved for first-line use,. Pharmacoecon. Outcomes News 518, 8 (2006). https://doi.org/10.2165/00151234-200605180-00026

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605180-00026

Keywords

Search

Navigation